PDL BioPharma — Q1 2019 Earnings Presentation
12 slides from PDL BioPharma's earnings presentation, May 9, 2019
Slide 1: 2019 First Quarter Financial Results Conference Call
PDL 2019 First Quarter Financial Results Conference Call May 9, 2019
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements including PDL's expectations with respect to its future royalty revenues, expenses, net income and cash provided by operating activities. Each of these forward-looking statements involves risks and uncertainties. Actual
Slide 3: Background on Evofem Biosciences
Background on Evofem Biosciences o Nasdaq listed: EVFM o Developing innovative products to address unmet needs in women’s sexual and reproductive health o Lead investigational drug product, Amphora® = An on-demand, non-hormonal gel contraceptive = Initially filed for approval in 2015 —CRL received d
Slide 4: Rationale for Our Investment in Evofem
Rationale for Our Investment in Evofem o Welike the therapeutic space = We identified women’s health as an area of strategic interest o Welike the Evofem team = Positive assessment of the Evofem CEO and management team o Welike Amphora as a novel product that addresses a significant unmet need and f
Slide 5: PDL's Advantages in Evofem Transaction
PDL’s Advantages in Evofem Transaction o Strong and liquid balance sheet = Allowed quick deployment of first tranche of funds o Commercialization experience = Enabled us to be credible in the negotiations with Evofem o Flexibility in deal structure = Allowed entry to opportunity = Allows for further
Slide 6: Evofem: Terms of Transaction
Evofem: Terms of Transaction o Potential total investment of $60 million by PDL o $30 million 18 tranche closed on April 11 = ~6.67 million shares of EVFM, plus = ~1.67 million common stock warrants of EVFM priced at $6.38 per share o $50 million 2" tranche decision on or before June 10 = Same per s
Slide 7: Share Repurchase Program Update
Share Repurchase Program Update o To date we have used $80.3 million to repurchase approximately 24.5 million shares at an average price of $3.27 per share under the $100 million share repurchase plan announced in September 2018 = Repurchased 8.7 million shares for $25.5 million in Q4 2018 = Repurch
Slide 8: LENSAR: Robust Growth and Continued Innovation
LENSAR: Robust Growth and Continued Innovation o LENSAR reported revenues of $6.7 million in Q1 2019 = 35 percent increase over Q1 2018 o Q1 2019 GAAP net loss of approximately $1.2 million = EBITDA net loss of approximately $600,000 o LENSAR technology helps surgeons increase their efficiency and p
Slide 9: Noden: Continued Focus on Profitability
Noden: Continued Focus on Profitability o Actions to increase the profitability of Tekturna® in the U.S. and mitigate the impact of generic competition include: = Launching authorized generic (AG) version of Tekturna (aliskiren) through Prasco Laboratories in anticipation of generic competition from
Slide 10: First Quarter 2019 Financials (unaudited)
First Quarter 2019 Financials (unaudited) Three Months Ended March 31, (In thousands, except per share amounts) 2019 2018 Product revenue, net $ 26686 $ 23,324 Royalty rights - change in fair value 412,257 411,094 Royalties from Queen et al. patents 3 2,783 Interest revenue z 749 License and other 3
Slide 11: First Quarter 2019 Financials (unaudited)
11 First Quarter 2019 Financials (unaudited) (in thousands) GAAP net income attributed to PDL’s shareholders as reported Adustments: Mark-to-market adjustment to fair value assets Non-cash interest revenues Non-cash stock-based compensation expense Non-cash debt offering costs Non-cash depreciation
Slide 12: First Quarter 2019 Financials (unaudited)
First Quarter 2019 Financials (unaudited) Consolidated balance sheet data (in thousands) March 31, December 31, 2019 2018 Cash and cash equivalents $ 366,324 $ 394,590 Total notes receivable $ 63,704 $ 63,813 Royalty rights - at fair value $ 376,147 $ 376,510 Intangible assets, net $ 49,746 $ 51,319